返回 Agenda
SESSION 10: BENEFIT-RISK MANAGEMENT PLAN – CASE STUDIES
Session Chair(s)
Jan Petracek, MD, MSC
CEO
iVigee Services a.s., Czech Republic
- Small molecules and generics
- Biologics and biosimilars
- Advanced therapies
- Combination therapies
Speaker(s)
Small Molecule Group Work
Michael Forstner, PHD, MPH, MSC
Mesa Laubela-Consulting, Switzerland
Managing Director, Head of Pharmacoepidemiology Practice
Combination Product Group Work
Jan Petracek, MD, MSC
iVigee Services a.s., Czech Republic
CEO
Biologic Group Work
Jan Petracek, MD, MSC
iVigee Services a.s., Czech Republic
CEO
Advanced Therapies Group Work
Jan Petracek, MD, MSC
iVigee Services a.s., Czech Republic
CEO